{"id":290920,"date":"2026-06-29T10:14:22","date_gmt":"2026-06-29T10:14:22","guid":{"rendered":"https:\/\/www.europesays.com\/se\/290920\/"},"modified":"2026-06-29T10:14:22","modified_gmt":"2026-06-29T10:14:22","slug":"synact-pharma-okat-partnerintresse-for-resomelagon-efter-advance-och-event","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/290920\/","title":{"rendered":"Synact Pharma: \u00d6kat partnerintresse f\u00f6r resomelagon efter Advance och event"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Synact Pharma uppger att intresset f\u00f6r resomelagon har \u00f6kat markant efter de positiva resultaten fr\u00e5n Advance-studien och bolagets deltagande p\u00e5 eventet BIO International i San Diego. Enligt bolaget har flera potentiella l\u00e4kemedelspartners lyft fram ACR20- och ACR50-resultaten, biomark\u00f6rsdata och s\u00e4kerhetsprofilen.\n <\/p>\n<p>Synact v\u00e4ntar ytterligare fas II-resultat senare i \u00e5r och forts\u00e4tter utv\u00e4rdera strategiska alternativ, inklusive partnerskap, licensavtal och f\u00f6retagsaff\u00e4rer, f\u00f6r att maximera programmets kommersiella potential.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Nyhetsbyr\u00e5n Finwire<\/p>\n","protected":false},"excerpt":{"rendered":"Synact Pharma uppger att intresset f\u00f6r resomelagon har \u00f6kat markant efter de positiva resultaten fr\u00e5n Advance-studien och bolagets&hellip;\n","protected":false},"author":2,"featured_media":290793,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,70,71,34,31,33,32,30,12427],"class_list":["post-290920","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-economy","tag-ekonomi","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish","tag-synact-pharma"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116832873178461145","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/290920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=290920"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/290920\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/290793"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=290920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=290920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=290920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}